{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:11:59Z","timestamp":1790345519111,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016257","name":"Inha University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.parkreldis.2021.01.004","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T21:43:21Z","timestamp":1610574201000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Impact of the apolipoprotein E \u03b54 allele on early Parkinson's disease progression"],"prefix":"10.1016","volume":"83","author":[{"given":"Ryul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-6118","authenticated-orcid":false,"given":"Dallah","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beomseok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2021.01.004_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2017-316213","article-title":"Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort","volume":"89","author":"Simuni","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2021.01.004_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3988\/jcn.2019.15.4.488","article-title":"Combined assessment of serum alpha-synuclein and Rab35 is a better biomarker for Parkinson's disease","volume":"15","author":"Wang","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","article-title":"Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease","volume":"126","author":"Zhang","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.14348\/molcells.2014.0248","article-title":"Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms","volume":"37","author":"Kim","year":"2014","journal-title":"Mol. Cell."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1809","article-title":"APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid","volume":"12","author":"Zhao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay3069","article-title":"APOE genotype regulates pathology and disease progression in synucleinopathy","volume":"12","author":"Davis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2021.01.004_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fncel.2018.00282","article-title":"Microglial implication in Parkinson's disease: loss of beneficial physiological roles or gain of inflammatory functions?","volume":"12","author":"Lecours","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mds.26374","article-title":"Baseline genetic associations in the Parkinson's progression markers initiative (PPMI)","volume":"31","author":"Nalls","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib12","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaneurol.2014.1455","article-title":"APOE, MAPT, SNCA, and cognitive performance in Parkinson disease","volume":"71","author":"Mata","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/bs.irn.2017.05.008","article-title":"Nonmotor effects of conventional and transdermal dopaminergic therapies in Parkinson's disease","volume":"134","author":"Kim","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/mds.25062","article-title":"Clinical differences among mild cognitive impairment subtypes in Parkinson's disease","volume":"27","author":"Goldman","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib16","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/mds.27845","article-title":"Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts","volume":"34","author":"Iwaki","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.parkreldis.2014.02.001","article-title":"Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status","volume":"20","author":"Monsell","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2021.01.004_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","article-title":"Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia","volume":"80","author":"Gomperts","year":"2013","journal-title":"Neurology"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:14:14Z","timestamp":1762370054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"alternative-id":["S1353802021000195"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.004","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the apolipoprotein E \u03b54 allele on early Parkinson's disease progression","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}